Denali Capital Acquisition CORP S-1 registration statements
Registration statements, filed ahead of a public offering, with the business description and financials a first-time investor sees.
Semnur Pharmaceuticals files an S-1/A registration statement detailing its recent business combination, ongoing clinical development for its lead non-opioid pain candidate SP-102, and significant financial losses.
Semnur Pharmaceuticals filed an S-1 registration statement, outlining its non-opioid pain product SP-102's development, recent business combination, and significant financial challenges including a going concern doubt.